About Clarence Wybon
With 14 years of experience spanning academia, the chemical sector, and the pharmaceutical industry, Clarence Wybon is a seasoned organic chemistry expert. In April 2026, she founded Clarbonyx, a specialized life science consultancy that is largely dedicated to navigating the complexities of pharmaceutical impurities. Below, Clarence shares insights into her professional journey and her approach to solving complex cases:
Clarence Wybon, founder of Clarbonyx
Testament to my commitment to lifelong learning, I possess a Master of Science in Bioscience Engineering: Chemistry and Bioprocess Technology and a Bachelor of Laws. This unique combination allows me to understand both the chemical intricacies of pharmaceutical development, such as API synthesis, formulation, scale-up, and impurities, and the regulatory frameworks governing them.
My career has been defined by navigating complex regulatory landscapes, leading international R&D and manufacturing initiatives, and driving technical advocacy to ensure organizational compliance and future-readiness. My forte is interpreting global regulatory signals and translating them into actionable strategies by building high-quality, evidence-based technical responses.
Apart from academic research experience in organic chemistry, I have industry experience in chemical and API manufacturing and at a global consumer health company active in OTC generics, where I acted for six years as the technical lead for the response to the call for review on nitrosamine impurities for a large and diverse portfolio. In addition, I drove new product development and reformulation initiatives, encompassing pharmaceuticals, cosmetics, food supplements, and medical devices.
As Principal Consultant at Clarbonyx, I continue to specialize in mutagenic and non-mutagenic pharmaceutical impurities and specifically nitrosamines. At the same time, my background allows me to tackle diverse chemistry- and formulation- oriented problems.
I act as an analytical multidisciplinary problem-solver who thrives on accountability and scientific creativity to solve complex problems. People see me as a knowledgeable, driven and detail-oriented, innovative thinker with a "can-do mentality" and a passion for making a mark for patients.
My approach is rooted in the intersection of rigorous academic theory and practical industrial application. Having spent over a decade deciphering chemical pathways and regulatory requirements, I founded Clarbonyx to bridge the gap between complex chemical challenges and actionable compliance solutions.
My approach is defined by:
Analytical Mindset: I treat every consulting engagement as a technical investigation, ensuring no variable is overlooked.
Deep Knowledge: I bring years of specialized experience, allowing me to foresee regulatory or technical pitfalls before they impact your timeline or freedom to operate.
Problem-Solving Clarity: I translate intense technical data into clear, actionable advice, ensuring you are empowered to lead your projects with confidence.
Education
Master of Science in Bioscience Engineering - Chemistry and Bioprocess Technology, Ghent University (2012)
Bachelor of Laws, KU Leuven (2023)
Operational safety certification “VCA - Veiligheid voor Operationeel Leidinggevenden” (VOL-VCA) (2020)
Green Belt in Lean (2017)
Publications and Patents
Hollanders, K., Renders, E., Gadais, C., Masullo, D., Van Raemdonck, L., Wybon, C. C. D., Martin, C., Herrebout, W. A., Maes, B. U. W., & Ballet, S. (2020). Zn-Catalyzed Nicotinate-Directed Transamidations in Peptide Synthesis. ACS Catalysis, 10(7), 4280–4289. https://doi.org/10.1021/acscatal.9b05074.
Ronson, T. O., Renders, E., Van Steijvoort, B. F., Wang, X., Wybon, C. C. D., Prokopcová, H., Meerpoel, L., & Maes, B. U. W. (2019). Ruthenium‐Catalyzed Reductive Arylation of N‐(2‐Pyridinyl)amides with Isopropanol and Arylboronate Esters. Angewandte Chemie International Edition, 131(2), 492–497. https://doi.org/10.1002/ange.201810947.
Wybon, C. C. D., Mensch, C., Hollanders, K., Gadais, C., Herrebout, W. A., Ballet, S., & Maes, B. U. W. (2018). Zn-Catalyzed tert-Butyl Nicotinate-Directed Amide Cleavage as a Biomimic of Metallo-Exopeptidase Activity. ACS Catalysis, 8(1), 203–218. https://doi.org/10.1021/acscatal.7b02599.
Process for the catalytic directed cleavage of amide-containing compounds. EP3362436A1; EP3362436B1; WO2017046133A1. Applicant: University of Antwerp; Inventors: Maes, B; Wybon, C.; Chen, C.; Bheeter, C. B.; Sergueev, S. Publication 2018-08-22.
Recycling of organotin compounds. EP2662379A1; WO2013167585 A2 (A3). Applicant: University of Antwerp; Inventors: Kuvshinov, A.; Franck, P.; Depraetere, S.; Maes, B.; De Houwer, J.; Wybon, C.; Sterckx, H.; Sergueev, S. Publication 2013-11-14.
Žukauskaitė, A., Mangelinckx, S., Callebaut, G., Wybon, C., Šačkus, A., & De Kimpe, N. (2013). Synthesis of 1,5-diazaspiro[2.3]hexanes, a novel diazaspirocyclic system. Tetrahedron, 69(16), 3437–3443. https://doi.org/10.1016/j.tet.2013.02.065.
Clarence Wybon actively engages in the Nitrosamines Research Program (NRP) of the HESI (Health and Environmental Sciences Institute) GTTC (Genetic Toxicology Technical Committee) Mechanism-based Genotoxicity Risk Assessment (MGRA) working group.
Engagement
Professional Working Groups & Committees